Comparative accuracy and resolution assessment of two prototype proton computed tomography scanners

Autor: George Dedes, Hubertus Drosten, Stefanie Götz, Jannis Dickmann, Christina Sarosiek, Mark Pankuch, Nils Krah, Simon Rit, Vladimir Bashkirov, Reinhard W. Schulte, Robert P. Johnson, Katia Parodi, Ethan DeJongh, Guillaume Landry

Publikováno v: Medical Physics. 49:4671-4681

Improving the accuracy of relative stopping power (RSP) in proton therapy may allow reducing range margins. Proton computed tomography (pCT) has been shown to provide state-of-the-art RSP accuracy estimation, and various scanner prototypes have recen

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aeb8c552ca626418d4b5a181f944a6e8
https://doi.org/10.1002/mp.15657

FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?†

Autor: Hossain Roshani, Laura S. Mertens, Y. Neuzillet, Núria Malats, Geert J.L.H. van Leenders, Markus Eckstein, Wolfgang Otto, Robert Stoehr, Ellen C. Zwarthoff, Damien Pouessel, Katrin Hippe, Yanish Soorojebally, Peter J. Boström, Maximilian Burger, Cheno Abas, Joost L. Boormans, Arndt Hartmann, Mirari Marquez, Michiel S. van der Heijden, Annegien Broeks, Joyce Sanders, Alexandre R. Zlotta, Stefanie Götz, Roman Mayr, Francisco X. Real, Nanor Sirab, Simone Bertz, Bas W.G. van Rhijn, Theo van der Kwast, Bernd Wullich, Tahlita C.M. Zuiverloon, François Radvanyi, Michael A.S. Jewett, Yves Allory

Publikováno v: European Urology, 78(5), 682-687. Elsevier
van Rhijn, B W G, Mertens, L S, Mayr, R, Bostrom, P J, Real, F X, Zwarthoff, E C, Boormans, J L, Abas, C, van Leenders, G J L H, Götz, S, Hippe, K, Bertz, S, Neuzillet, Y, Sanders, J, Broeks, A, van der Heijden, M S, Jewett, M A S, Marquez, M, Stoehr, R, Zlotta, A R, Eckstein, M, Soorojebally, Y, Roshani, H, Burger, M, Otto, W, Radvanyi, F, Sirab, N, Pouessel, D, Wullich, B, van der Kwast, T H, Malats, N, Hartmann, A, Allory, Y & Zuiverloon, T C M 2020, ' FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy : Implications for Anti-FGFR3 Treatment? † ', European Urology, vol. 78, no. 5, pp. 682-687 . https://doi.org/10.1016/j.eururo.2020.07.002
European urology, 78(5), 682-687. Elsevier

Fibroblast growth factor receptor 3 (FGFR3) is an actionable target in bladder cancer (BC). FGFR3 mutations are common in noninvasive BC and associated with favorable BC prognosis. Overexpression was reported in up to 40% of FGFR3 wild-type muscle-in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a7743d0b7c28a8e37a135fb3dd59f74
http://www.scopus.com/inward/record.url?scp=85087994866&partnerID=8YFLogxK

Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients

Autor: Laura S. Mertens, Francesco Claps, Roman Mayr, Peter J. Bostrom, Shahrokh F. Shariat, Ellen C. Zwarthoff, Joost L. Boormans, Cheno Abas, Geert J.L.H. van Leenders, Stefanie Götz, Katrin Hippe, Simone Bertz, Yann Neuzillet, Joyce Sanders, Annegien Broeks, Dennis Peters, Michiel S. van der Heijden, Michael A.S. Jewett, Robert Stöhr, Alexandre R. Zlotta, Markus Eckstein, Yanish Soorojebally, Deric K.E. van der Schoot, Bernd Wullich, Maximilian Burger, Wolfgang Otto, François Radvanyi, Nanour Sirab, Damien Pouessel, Theo H. van der Kwast, Arndt Hartmann, Yair Lotan, Yves Allory, Tahlita C.M. Zuiverloon, Bas W.G. van Rhijn

Publikováno v: Urologic Oncology: Seminars and Original Investigations, 40(3), 110.e1-110.e9. Elsevier Inc.

Objectives: To determine the association between the FGFR3 mutation status and immuno-histochemistry (IHC) markers (p53 and Ki-67) in invasive bladder cancer (BC), and to analyze their prognostic value in a multicenter, multi-laboratory radical cyste

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4b2fb2ceafd5b988072aeaf106e1292
https://doi.org/10.1016/j.urolonc.2021.10.010

Heterogeneity of astrocytes: Electrophysiological properties of juxtavascular astrocytes before and after brain injury

Autor: Magdalena Götz, Lars Kunz, Ana Bribián, Benedikt Grothe, Stefanie Götz, Laura López-Mascaraque

Publikováno v: Glia 69, 346-361 (2020)
Digital.CSIC. Repositorio Institucional del CSIC
instname

Astrocyte heterogeneity is increasingly recognized, but still little is known about juxtavascular astrocytes with their somata directly adjacent to blood vessels, despite their importance after brain injury. As juxtavascular astrocytes originate from

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dff5998ea09100ed3e871d254f096044
https://push-zb.helmholtz-muenchen.de/frontdoor.php?source_opus=59920

Abstract B23: FGFR3 mutations and their relation to FGFR3 expression and clinical outcome in a large radical cystectomy cohort: Implications for anti-FGFR3 bladder cancer treatment?

Autor: Michiel S. van der Heijden, Tahlita C.M. Zuiverloon, Stefanie Götz, E.C. Zwarthoff, P.J. Bostrom, Theo van der Kwast, Roman Mayr, Laura S. Mertens, Markus Eckstein, François Radvanyi, F.X. Real, Yves Allory, Damien Pouessel, Yanish Soorojebally, Michael A.S. Jewett, N. Malats, Bas W.G. van Rhijn, Mirari Marques, Robert Stöhr, Alexandre R. Zlotta, Deric K. Van der Schoot, Geert J. L. H. van Leenders, Arndt Hartmann, Wolfgang Otto, Max Bürger

Publikováno v: Clinical Cancer Research. 26:B23-B23

Objective: Fibroblast growth factor receptor 3 (FGFR3) is a potentially actionable target in bladder cancer (BC). FGFR3 mutations are associated with favorable prognosis in non-muscle invasive (NMI) BC and MIBC. Overexpression of FGFR3 was reported i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c8768b33e0b650a134160739a6f2e9f6
https://doi.org/10.1158/1557-3265.bladder19-b23